HE 20.4208/2:An 8/2
|
Guidelines for the clinical evaluation of antidepressant drugs. |
1 |
HE 20.4208/2:An 8/3
|
Guidelines for the clinical evaluation of anti-infective drugs (systemic) : adults and children. |
1 |
HE 20.4208/2:An 8/4
|
Guidelines for the clinical evaluation of antianxiety drugs. |
1 |
HE 20.4208/2:An 8/5
|
Guidelines for the clinical evaluation of antidiarrheal drugs. |
1 |
HE 20.4208/2:An 8/6
|
Guidelines for the clinical evaluation of anti-anginal drugs. |
1 |
HE 20.4208/2:An 8/7
|
Guidelines for the clinical evaluation of anti-inflammatory drugs (adults and children) |
1 |
HE 20.4208/2:An 8/8
|
Guidelines for the clinical evaluation of anti-arrhythmic drugs. |
1 |
HE 20.4208/2:An 8/9
|
Guidelines for the clinical evaluation of antacid drugs. |
1 |
HE 20.4208/2:An 8/10
|
Guidelines for the clinical evaluation of antiepileptic drugs (adults and children) |
1 |
HE 20.4208/2:An 8/11
|
Guidelines for the clinical evaluation of antineoplastic drugs. |
1 |
HE 20.4208/2:B 78
|
Guidelines for the clinical evaluation of bronchodilator drugs. |
1 |
HE 20.4208/2:C 19
|
Guidelines for the clinical evaluation of drugs to prevent dental caries. |
1 |
HE 20.4208/2:C 61
|
General considerations for the clinical evaluation of drugs. |
1 |
HE 20.4208/2:G 21
|
Guidelines for the clinical evaluation of gastric secretory depressant (GSD) drugs. |
1 |
HE 20.4208/2:G 21/2
|
Guidelines for the clinical evaluation of G.I. motility-modifying drugs. |
1 |
HE 20.4208/2:H 99
|
Guidelines for the clinical evaluation of hypnotic drugs. |
1 |
HE 20.4208/2:In 3
|
General considerations for the clinical evaluation of drugs in infants and children. |
1 |
HE 20.4208/2:L 45
|
Guidelines for the clinical evaluation of laxative drugs. |
1 |
HE 20.4208/2:L 66
|
Guidelines for the clinical evaluation of lipid-altering agents in adults and children. |
1 |
HE 20.4208/2:Os 7
|
Guidelines for the clinical evaluation of drugs used in the treatment of osteoporosis. |
1 |